Overview
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Eligibility
Inclusion Criteria:
- Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment
Exclusion Criteria:
- Unwilling to participate in the BioDay registry
- (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank